Corti launches new FactsR system for clinical consultations
Healthcare technology company Corti has introduced FactsR, a real-time agentic reasoning system designed for clinical consultations.
This system aims to lessen 'note bloat' driven by general-purpose AI by 65%, ensuring that medical records remain precise and relevant to the actual clinical conversation.
FactsR stands out from traditional large language model (LLM) pipelines adapted for healthcare by utilising Corti's recursive fact-first reasoning loop.
By minimising the need for post-visit edits and transforming passive transcripts into active clinical intelligence, FactsR paves the way for real-time decision support directly at the point of care.
Offered as a modular API, the system enables developers to integrate clinical-grade intelligence into healthcare applications, fostering safer AI experiences.
It allows for the creation of AI that delivers concise and accurate results, which clinicians can interact with during consultations.
FactsR operates in four key areas. Firstly, it listens and extracts structured clinical facts in real-time, such as symptoms and medications, during the consultation.
Secondly, each fact is vetted and refined through a specialised AI-driven feedback loop, ensuring accuracy and consistency.
Later on, clinicians have the opportunity to review and adjust the facts, maintaining control and complementing clinical judgement.
Lastly, the system generates electronic health record (EHR)-ready notes that are concise and free from irrelevant content, leading to reduced screen time and improved focus on the patient.
Corti.ai chief technology officer and co-founder Lars Maaløesaid: 'By breaking conversations into structured clinical facts and validating each one through recursive reasoning, FactsR elevates ambient documentation into a foundation for real-time clinical intelligence.
'When AI can listen, understand, and reason with medical context, it becomes more than a scribe - it becomes a trusted collaborator. With a developer-friendly API, we're enabling any healthtech company to embed this capability directly into their applications - safely, scalably, and in minutes.'
In October 2024, Corti announced a collaboration with US-based Tanner Health and its subsidiary Healthliant Ventures.
"Corti launches new FactsR system for clinical consultations" was originally created and published by Hospital Management, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Kingsoft Cloud Announces Unaudited First Quarter 2025 Financial Results
BEIJING, May 28, 2025 /PRNewswire/ -- Kingsoft Cloud Holdings Limited ("Kingsoft Cloud" or the "Company") (NASDAQ: KC and HKEX: 3896), a leading cloud service provider in China, today announced its unaudited financial results for the first quarter ended March 31,2025. Mr. Tao Zou, Chief Executive Officer of Kingsoft Cloud, commented, "Despite uncertainties in global supply chain, we believe the importance for cloud services as infrastructure in the AI-era is gaining greater traction. This quarter, our gross billing of AI business increased by 228% year- over-year to RMB525 million, accounting for 39% of our public cloud services. We are confident and fully committed into our AI related investment and high-quality and sustainable business development." Mr. Henry He, Chief Financial Officer of Kingsoft Cloud, added, "Our revenue increased by 10.9% year-over-year, achieving RMB1,970.0 million for the first quarter; however sequentially we experienced seasonal decrease. Our adjusted gross profit was RMB327.7 million, increased by 9.6% year-over-year and decreased by 23.4% quarter-over-quarter. Adjusted gross margin was 16.6% in this quarter, compared with 16.8% in the first quarter 2024 and 19.2% in the fourth quarter last year. Our adjusted operating loss was RMB55.8 million, narrowed by 56% from RMB127.0 million in the same period last year. Our adjusted EBITDA profit achieved RMB318.5 million, representing an adjusted EBITDA margin of 16.2%" First Quarter 2025 Financial Results Total Revenues reached RMB1,970.0 million (US$271.5[1] million), increased by 10.9% year-over-year from RMB1,775.7 million in the same quarter of 2024 and decreased by 11.7% quarter-over-quarter from RMB2,232.1million in the fourth quarter of 2024. The year-over-year increase was mainly due to the expanded revenue from Xiaomi and Kingsoft Ecosystem and AI related customers and our further penetration into enterprise cloud customers. The quarter-over-quarter decrease was mainly due to the seasonality impact for enterprise cloud. Revenues from public cloud services were RMB1,353.5 million (US$186.5 million), increased by 14.0% from RMB1,187.4 million in the same quarter of 2024 and decreased by 4.0% from RMB1,409.8 million last quarter. The year-over-year increase was mainly due to the growth of AI demands. Revenues from enterprise cloud services were RMB616.5 million (US$85.0 million), representing an increase of 4.8% from RMB588.2 million in the same quarter of 2024 and a decrease of 25.0% from RMB822.3 million last quarter. The sequential decrease was mainly due to the Chinese New Year impact and differentiated delivery schedules for various projects. Other revenues were nil this quarter. Cost of revenues was RMB1,651.7 million (US$227.6 million), representing an increase of 11.4% from RMB1,482.4 million in the same quarter of 2024, which was mainly due to our investment into AI computing resources. IDC costs decreased by 6.0% year-over-year from RMB768.5 million to RMB722.8 million (US$99.6 million) this quarter. The decrease was mainly due to our strict control over procurement costs. Depreciation and amortization costs increased from RMB183.5 million in the same quarter of 2024 to RMB378.5 million (US$52.2 million) this quarter. The increase was mainly due to the depreciation of newly acquired servers which were allocated to AI business. Solution development and services costs increased by 13.3% year-over-year from RMB446.0 million in the same quarter of 2024 to RMB505.2 million (US$69.6 million) this quarter. The increase was mainly due to the solution personnel expansion of Camelot. Fulfillment costs and other costs were RMB3.1 million (US$0.4 million) and RMB42.1 million (US$5.8 million) this quarter. Gross profit was RMB318.3 million (US$43.9 million), representing an increase of 8.5% from RMB293.3 million in the same quarter of 2024, demonstrating our improvements in revenue quality and structure. Gross margin was 16.2%, remaining stable compared with 16.5% in the same period in 2024. Non-GAAP gross profit[2] was RMB327.7 million (US$45.2 million), compared with RMB299.1 million in the same period in 2024. Non-GAAP gross margin[2] was 16.6%, compared with 16.8% in the same period in 2024. The improvement of our gross profit was mainly due to the decrease of procurement costs. The sequential decrease of gross margin was mainly due to the growing investment into AI and the delay of high-margin profile enterprise cloud projects in first quarter. Total operating expenses were RMB552.5 million (US$76.1 million), decreased by 2.6% from RMB567.4 million in the same quarter last year and increased by 17.7% from RMB469.5 million last quarter. Among which: Selling and marketing expenses were RMB144.3 million (US$19.9 million), increased by 23.6% from RMB116.8 million in the same period in 2024 and increased by 24.7% from RMB115.8 million last quarter. The increase was due to the increase of one-time-off bonus of share based compensation. General and administrative expenses were RMB182.0million (US$25.1million), decreased by 16.8% from RMB218.7 million in the same period in 2024 and slightly increased by 1.4% from RMB179.5 million last quarter. The year-over-year decrease was mainly due to the decrease of credit loss expense, which was partially offset by the increase of share based compensation. Research and development expenses were RMB226.2 million (US$31.2 million), decreased by 2.5% from RMB232.0 million in the same period in 2024 and increased by 29.9% from RMB174.2 million last quarter. The increase was mainly due to our continuous investment into research and development personnel to enhance our technology competitiveness and increase of share based compensation. Operating loss was RMB234.2 million (US$32.3 million), compared with operating loss of RMB274.2 million in the same quarter of 2024 and RMB43.5 million last quarter. The year-over-year improvement was mainly due to the increase of gross profit and our strict expenses control, while the sequential increase was mainly due to the impact of gross profit and increase of shared based compensation. Non-GAAP operating loss[3] was RMB55.8 million (US$7.7 million), compared with operating loss of RMB127.0 million in the same quarter last year and operating profit of RMB24.4 million last quarter. Net loss was RMB316.1 million (US$43.6 million), compared with net loss of RMB363.6 million in the same quarter of 2024 and RMB200.6 million last quarter. Non-GAAP net loss[4] was RMB190.6 million (US$26.3 million), compared with RMB217.3 million in the same quarter of 2024 and RMB70.3 million last quarter. The year-over-year improvement was mainly due to the revenue quality increase, revenue mix adjustment, strict costs control and expenses control. The quarter-over-quarter decrease was mainly due to the seasonality impact. Non-GAAP EBITDA[5] was RMB318.5 million (US$43.9 million), compared with RMB33.2 million in the same quarter of 2024 and RMB359.7 million last quarter. Non-GAAP EBITDA margin was 16.2%, compared with 1.9% in the same quarter of 2024 and 16.1% in the previous quarter. The increase was mainly due to the expansion of AI businesses with higher margin. Basic and diluted net loss per share was RMB0.08 (US$0.01), compared with RMB0.10 in the same quarter of 2024 and RMB0.05 last quarter. Cash and cash equivalents were RMB2,322.7 million (US$320.1 million) as of March 31, 2025, compared with RMB2,648.8 million as of December 31, 2024. The decrease was mainly due to the investment into operation and the investment into the procurement of computing power equipment. Outstanding ordinary shares were 3,703,014,637 as of March 31, 2025, equivalent to about 246,867,642 ADSs. [1] This announcement contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) at a specified rate solely for the convenience of the reader. Unless otherwise noted, the translation of RMB into US$ has been made at RMB7.2567 to US$1.00, the noon buying rate in effect on March 31, 2025 as certified for customs purposes by the Federal Reserve Bank of New York. [2] Non-GAAP gross profit is defined as gross profit excluding share-based compensation allocated in the cost of revenues and we define Non-GAAP gross margin as Non-GAAP gross profit as a percentage of revenues. See "Use of Non-GAAP Financial Measures" set forth at the end of this press release. [3] Non-GAAP operating (loss) profit is defined as operating loss excluding share-based compensation and amortization of intangible assets and we define Non-GAAP operating (loss) profit margin as Non-GAAP operating (loss) profit as a percentage of revenues. See "Use of Non-GAAP Financial Measures" set forth at the end of this press release. [4] Non-GAAP net loss is defined as net loss excluding share-based compensation and foreign exchange loss (gain), and we define Non-GAAP net loss margin as adjusted net loss as a percentage of revenues. See "Use of Non-GAAP Financial Measures" set forth at the end of this press release. [5] Non-GAAP EBITDA is defined as Non-GAAP net loss excluding interest income, interest expense, income tax (benefit) expense and depreciation and amortization, and we define Non-GAAP EBITDA margin as Non-GAAP EBITDA as a percentage of revenues. See "Use of Non-GAAP Financial Measures" set forth at the end of this press release. Conference Call Information Kingsoft Cloud's management will host an earnings conference call on Wednesday, May 28, 2025 at 8:15 am, U.S. Eastern Time (8:15 pm, Beijing/Hong Kong Time on the same day). Participants can register for the conference call by navigating to Once preregistration has been completed, participants will receive dial-in numbers, direct event passcode, and a unique access PIN. To join the conference, simply dial the number in the calendar invite you receive after preregistering, enter the passcode followed by your PIN, and you will join the conference instantly. Additionally, a live and archived webcast of the conference call will also be available on the Company's investor relations website at Use of Non-GAAP Financial Measures The unaudited condensed consolidated financial information is prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). In evaluating our business, we consider and use certain non-GAAP measures, Non-GAAP gross profit, Non-GAAP gross margin, Non-GAAP operating (loss) profit, Non-GAAP operating (loss) profit margin, Non-GAAP EBITDA, Non-GAAP EBITDA margin, Non-GAAP net loss and Non-GAAP net loss margin, as supplemental measures to review and assess our operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define Non-GAAP gross profit as gross profit excluding share-based compensation allocated in the cost of revenues, and we define Non-GAAP gross margin as Non-GAAP gross profit as a percentage of revenues. We define Non-GAAP operating (loss) profit as operating loss excluding share-based compensation and amortization of intangible assets and we define Non-GAAP operating (loss) profit margin as Non-GAAP operating (loss) profit as a percentage of revenues. We define Non-GAAP net loss as net loss excluding share-based compensation and foreign exchange loss (gain), and we define Non-GAAP net loss margin as Non-GAAP net loss as a percentage of revenues. We define Non-GAAP EBITDA as Non-GAAP net loss excluding interest income, interest expense, income tax (benefit) expense and depreciation and amortization, and we define Non-GAAP EBITDA margin as Non-GAAP EBITDA as a percentage of revenues. We present these non-GAAP financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We also believe that the use of these non-GAAP measures facilitates investors ' assessment of our operating performance. These non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. These non-GAAP financial measures have limitations as analytical tools. One of the key limitations of using these non-GAAP financial measures is that they do not reflect all items of income and expense that affect our operations. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited. We compensate for these limitations by reconciling these non-GAAP financial measures to the nearest U.S. GAAP performance measure, all of which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure. Exchange Rate Information This press release contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from RMB to U.S. dollars, in this press release, were made at a rate of RMB7.2567 to US$1.00, the noon buying rate in effect on March 31, 2025 as certified for customs purposes by the Federal Reserve Bank of New York. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the " safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the Business Outlook, and quotations from management in this announcement, as well as Kingsoft Cloud's strategic and operational plans, contain forward-looking statements. Kingsoft Cloud may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Kingsoft Cloud's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Kingsoft Cloud's goals and strategies; Kingsoft Cloud's future business development, results of operations and financial condition; relevant government policies and regulations relating to Kingsoft Cloud 's business and industry; the expected growth of the cloud service market in China; the expectation regarding the rate at which to gain customers, especially Premium Customers; Kingsoft Cloud's ability to monetize the customer base; fluctuations in general economic and business conditions in China; and the economy in China and elsewhere generally; China's political or social conditions and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Kingsoft Cloud's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Kingsoft Cloud does not undertake any obligation to update any forward-looking statement, except as required under applicable law. About Kingsoft Cloud Holdings Limited Kingsoft Cloud Holdings Limited (NASDAQ: KC and HKEX:3896) is a leading cloud service provider in China. With extensive cloud infrastructure, cutting-edge cloud-native products based on vigorous cloud technology research and development capabilities, well-architected industry-specific solutions and end-to-end fulfillment and deployment, Kingsoft Cloud offers comprehensive, reliable and trusted cloud service to customers in strategically selected verticals. For more information, please visit: For investor and media inquiries, please contact: Kingsoft Cloud Holdings Limited Nicole ShanTel: +86 (10) 6292-7777 Ext. 6300Email: ksc-ir@ KINGSOFT CLOUD HOLDINGS LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (All amounts in thousands)Dec 31,2024 Mar 31,2025 Mar 31,2025RMB RMB US$ ASSETSCurrent assets:Cash and cash equivalents 2,648,764 2,322,674 320,073 Restricted cash 81,337 63,670 8,774 Accounts receivable, net 1,468,663 1,807,011 249,013 Short-term investments 90,422 60,245 8,302 Prepayments and other assets 2,233,074 2,254,813 310,722 Amounts due from related parties 318,526 629,876 86,799 Total current assets 6,840,786 7,138,289 983,683 Non-current assets:Property and equipment, net 4,630,052 6,514,205 897,681 Intangible assets, net 694,880 660,926 91,078 Goodwill 4,605,724 4,605,724 634,686 Prepayments and other assets 449,983 444,555 61,261 Equity investments 234,182 232,790 32,079 Operating lease right-of-use assets 137,047 124,585 17,168 Total non-current assets 10,751,868 12,582,785 1,733,953 Total assets 17,592,654 19,721,074 2,717,636 LIABILITIES, NON-CONTROLLING INTERESTS AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable 1,877,004 2,040,574 281,199 Accrued expenses and other current liabilities 3,341,990 3,616,908 498,423 Short-term borrowings 2,225,765 2,550,970 351,533 Income tax payable 69,219 75,532 10,409 Amounts due to related parties 1,584,199 1,471,400 202,764 Current operating lease liabilities 61,258 42,459 5,851 Total current liabilities 9,159,435 9,797,843 1,350,179 Non-current liabilities:Long-term borrowings 1,660,584 1,997,371 275,245 Amounts due to related parties 309,612 494,982 68,210 Deferred tax liabilities 101,677 89,725 12,364 Other liabilities 790,271 1,932,576 266,316 Non-current operating lease liabilities 65,755 63,932 8,810 Total non-current liabilities 2,927,899 4,578,586 630,945 Total liabilities 12,087,334 14,376,429 1,981,124 Shareholders' equity:Ordinary shares 25,689 25,689 3,540 Treasury stock (105,478) (88,114) (12,142) Additional paid-in capital 18,940,885 19,071,212 2,628,083 Statutory reserves funds 32,001 32,001 4,410 Accumulated deficit (14,291,957) (14,605,883) (2,012,744) Accumulated other comprehensive income 566,900 574,660 79,190 Total Kingsoft Cloud Holdings Limited shareholders' equity 5,168,040 5,009,565 690,337 Non-controlling interests 337,280 335,080 46,175 Total equity 5,505,320 5,344,645 736,512 Total liabilities, non-controlling interests and shareholders' equity 17,592,654 19,721,074 2,717,636 KINGSOFT CLOUD HOLDINGS LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (All amounts in thousands, except for share and per share data)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Mar 31,2025RMB RMB RMB US$ Revenues: Public cloud services 1,187,370 1,409,804 1,353,479 186,514 Enterprise cloud services 588,162 822,338 616,498 84,956 Others 152 - - - Total revenues 1,775,684 2,232,142 1,969,977 271,470 Cost of revenues (1,482,431) (1,806,170) (1,651,671) (227,606) Gross profit 293,253 425,972 318,306 43,864 Operating expenses: Selling and marketing expenses (116,752) (115,792) (144,338) (19,890) General and administrative expenses (218,695) (179,536) (181,999) (25,080) Research and development expenses (231,963) (174,155) (226,170) (31,167) Total operating expenses (567,410) (469,483) (552,507) (76,137) Operating loss (274,157) (43,511) (234,201) (32,273) Interest income 8,370 4,176 4,946 682 Interest expense (51,066) (61,821) (82,897) (11,424) Foreign exchange (loss) gain (42,737) (105,572) 9,051 1,247 Other (loss) gain, net (8,207) (2,956) 3,244 447 Other (expense) income, net (11,190) 5,336 (7,012) (966) Loss before income taxes (378,987) (204,348) (306,869) (42,287) Income tax benefit (expense) 15,371 3,706 (9,241) (1,273) Net loss (363,616) (200,642) (316,110) (43,560) Less: net loss attributable to non-controlling interests (4,206) (3,683) (2,184) (301) Net loss attributable to Kingsoft Cloud Holdings Limited (359,410) (196,959) (313,926) (43,259)Net loss per share: Basic and diluted (0.10) (0.05) (0.08) (0.01) Shares used in the net loss per share computation: Basic and diluted 3,614,662,846 3,710,632,202 3,728,092,123 3,728,092,123 Other comprehensive income, net of tax of nil: Foreign currency translation adjustments 20,704 103,658 7,744 1,067 Comprehensive loss (342,912) (96,984) (308,366) (42,493) Less: Comprehensive loss attributable to non-controlling interests (4,247) (3,667) (2,200) (303) Comprehensive loss attributable to Kingsoft Cloud Holdings Limited shareholders (338,665) (93,317) (306,166) (42,190) KINGSOFT CLOUD HOLDINGS LIMITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, except for percentage)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Mar 31,2025RMB RMB RMB US$ Gross profit 293,253 425,972 318,306 43,864 Adjustments: – Share-based compensation expenses (allocated in cost of revenues) 5,814 1,726 9,365 1,291 Adjusted gross profit (Non-GAAP Financial Measure) 299,067 427,698 327,671 45,155 KINGSOFT CLOUD HOLDINGS LIMITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, except for percentage)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Gross margin 16.5 % 19.1 % 16.2 % Adjusted gross margin (Non-GAAP Financial Measure) 16.8 % 19.2 % 16.6 % KINGSOFT CLOUD HOLDINGS LIMITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, except for percentage)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Mar 31,2025RMB RMB RMB US$ Net Loss (363,616) (200,642) (316,110) (43,560) Adjustments: – Share-based compensation expenses 103,595 24,774 134,611 18,550 – Foreign exchange loss (gain) 42,737 105,572 (9,051) (1,247) Adjusted net loss (Non-GAAP Financial Measure) (217,284) (70,296) (190,550) (26,257) Adjustments: – Interest income (8,370) (4,176) (4,946) (682) – Interest expense 51,066 61,821 82,897 11,424 – Income tax (benefit) expense (15,371) (3,706) 9,241 1,273 – Depreciation and amortization 223,146 376,100 421,901 58,140 Adjusted EBITDA (Non-GAAP Financial Measure) 33,187 359,743 318,543 43,898 – Gain on disposal of property and equipment (23,821) (10,137) (2,110) (291) Excluding gain on disposal of property and equipment, normalized Adjusted EBITDA 9,366 349,606 316,433 43,607 KINGSOFT CLOUD HOLDINGS LIMITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, except for percentage)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Mar 31,2025RMB RMB RMB US$ Operating loss (274,157) (43,511) (234,201) (32,273) Adjustments: – Share-based compensation expenses 103,595 24,774 134,611 18,550 – Amortization of intangible assets 43,517 43,104 43,781 6,033 Adjusted operating (loss) profit (Non-GAAP Financial Measure) (127,045) 24,367 (55,809) (7,690) – Gain on disposal of property and equipment (23,821) (10,137) (2,110) (291) Excluding gain on disposal of property and equipment, normalized Adjusted operating (loss) profit (150,866) 14,230 (57,919) (7,981) KINGSOFT CLOUD HOLDINGS LIMITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS (All amounts in thousands, except for percentage)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Net loss margin -20.5 % -9.0 % -16.0 % Adjusted net loss margin (Non-GAAP Financial Measure) -12.2 % -3.1 % -9.7 % Adjusted EBITDA margin (Non-GAAP Financial Measure) 1.9 % 16.1 % 16.2 % Normalized Adjusted EBITDA margin 0.5 % 15.7 % 16.1 % Adjusted operating (loss) profit margin (Non-GAAP Financial Measure) -7.2 % 1.1 % -2.8 % Normalized Adjusted operating (loss) profit margin -8.5 % 0.6 % -2.9 % KINGSOFT CLOUD HOLDINGS LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (All amounts in thousands)Three Months EndedMar 31,2024 Dec 31,2024 Mar 31,2025 Mar 31,2025RMB RMB RMB US$ Net cash (used in) generated from operating activities (321,336) 570,222 (418,390) (57,656) Net cash used in investing activities (1,169,017) (1,337,978) (490,393) (67,578) Net cash generated from financing activities 1,112,096 1,802,762 549,998 75,792 Effect of exchange rate changes on cash, cash equivalents and restricted cash (20,464) (15,294) 15,028 2,071 Net (decrease) increase in cash, cash equivalents and restricted cash (398,721) 1,019,712 (343,757) (47,371) Cash, cash equivalents and restricted cash at beginning of period 2,489,481 1,710,389 2,730,101 376,218 Cash, cash equivalents and restricted cash at end of period 2,090,760 2,730,101 2,386,344 328,847 View original content: SOURCE Kingsoft Cloud Holdings Limited Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Protein Chips Industry Analysis (2025-2030) Featuring Strategic Profiles of 42 Market Players Including Abcam, Agilent and Roche Diagnostics
As precision medicine rises, protein chips play a pivotal role in diagnostics and drug discovery, with applications expanding in oncology, autoimmune disorders, and environmental testing. Regionally, the U.S. market was valued at $633.4 million in 2024, while China is anticipated to grow at a 6% CAGR to $552.8 million by 2030. Major players include Abcam, Agilent, and Roche Diagnostics. Protein Chips Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Protein Chips - Global Strategic Business Report" has been added to global market for Protein Chips was valued at US$2.4 Billion in 2024 and is projected to reach US$3.4 Billion by 2030, growing at a CAGR of 6.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Protein Chips market. The growth in the protein chips market is driven by several factors stemming from advancements in microarray technology, broader end-use applications, and increased demand for personalized medicine. Technologically, innovations in signal detection, miniaturization, and chip reproducibility are making protein chips more powerful and accessible. End-use growth is seen in pharmaceutical R&D, molecular diagnostics, and point-of-care testing, where fast and multiplexed protein analysis is critical. Consumers especially in wellness and genomics are also driving demand for individualized proteomic data, supporting use cases in preventive healthcare. Further, the expansion of proteomics infrastructure in Asia-Pacific and increased public-private research funding are contributing to the global scaling of protein chip manufacturing and adoption. These converging trends are establishing protein chips as a linchpin technology in modern biomedical research and diagnostics. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Abcam plc, Agilent Technologies Inc., Arrayit Corporation, Ayoxxa Biosystems GmbH, and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Analytical Microarrays segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of a 4.5%. The Functional Protein Microarrays segment is also set to grow at 8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $633.4 Million in 2024, and China, forecasted to grow at an impressive 6.0% CAGR to reach $552.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Why You Should Buy This Report: Detailed Market Analysis: Access a thorough analysis of the Global Protein Chips Market, covering all major geographic regions and market segments. Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies. Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Protein Chips Market. Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions. Key Questions Answered: How is the Global Protein Chips Market expected to evolve by 2030? What are the main drivers and restraints affecting the market? Which market segments will grow the most over the forecast period? How will market shares for different regions and segments change by 2030? Who are the leading players in the market, and what are their prospects? Some of the 42 companies featured in this Protein Chips market report include: Abcam plc Agilent Technologies Inc. Arrayit Corporation Ayoxxa Biosystems GmbH Bio-Rad Laboratories Inc. CDI Laboratories Inc. Danaher Corporation Full Moon BioSystems Inc. Illumina Inc. Innopsys S.A. Luminex Corporation Microarrays Inc. OriGene Technologies Inc. PerkinElmer Inc. RayBiotech Inc. Roche Diagnostics Sengenics Corporation Pte Ltd. Shimadzu Corporation Sigma-Aldrich Corporation Thermo Fisher Scientific Inc. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes Report Attribute Details No. of Pages 216 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $2.4 Billion Forecasted Market Value (USD) by 2030 $3.4 Billion Compound Annual Growth Rate 6% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Protein Chips - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Increasing Focus on Personalized Medicine Propels Demand for High-Throughput Protein Analysis Growth in Biomarker Discovery and Disease Profiling Expands Applications in Oncology and Neurology Rising Adoption of Multiplexed Assays Accelerates Use in Drug Development Pipelines Integration of AI and Machine Learning Enhances Data Interpretation and Diagnostic Accuracy Expansion of Proteomics Research in Academic Institutions Drives Product Demand Technological Advancements in Microarray Surface Chemistry Strengthen Analytical Performance Growing Prevalence of Chronic Diseases Spurs Use of Protein Chips in Clinical Diagnostics Miniaturization and Automation of Laboratory Processes Propel Adoption in Research Settings Government Funding for Life Sciences R&D Supports Market Growth Across Developed Nations Partnerships Between Biotech Firms and CROs Increase Commercialization of Custom Protein Arrays Increased Interest in Immune Profiling and Vaccine Development Boosts Segment Demand Shift Toward Point-of-Care Diagnostics Expands Use of Lab-on-a-Chip Solutions Rising Throughput Requirements in Genomic-Proteomic Integration Strengthens Market Appeal Emergence of Next-Gen Antibody-Based Chips Drives Innovation and Competitive Differentiation Regulatory Advancements and Approval Pathways Facilitate Clinical Use of Protein Microarrays For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Protein Chips Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Business Upturn
38 minutes ago
- Business Upturn
Flow Cytometry Market Hits US$10.3B by 2032: Why Every Lab Needs a FACS Flow Cytometer?
Delray Beach, FL, June 13, 2025 (GLOBE NEWSWIRE) — Ever wondered how scientists peek inside our cells, analyzing their secrets to diagnose diseases or develop life-saving therapies? It's all thanks to flow cytometry, a dynamic field transforming healthcare and research. And at its core, the remarkable FACS flow cytometer market leads the charge, offering unparalleled precision in analyzing and sorting cells. Imagine a sophisticated, high-speed sorting machine for microscopic cells. That's essentially what a flow cytometer machine does, and the FACS flow cytometer excels, providing meticulous insights into everything from cell cycle flow to identifying disease-causing biomarkers. Download PDF Brochure: This market is exploding, projected to jump from US$5.1 billion in 2024 to US$10.3 billion by 2032, growing at a robust 9.2% CAGR. What's fueling this surge? Rapid technological advancements (especially in FACS flow cytometer systems), increasing adoption in clinical diagnostics, rising chronic disease rates, booming biopharmaceutical R&D, and the urgent demand for precision medicine. Even AI and machine learning are boosting data analysis, accelerating this growth. Why the Buzz? Opportunities & Challenges in Flow Cytometry The global flow cytometry market offers exciting opportunities, but it's not without hurdles: Drivers: Innovation Pushes Boundaries The market thrives on new, advanced flow cytometry products and flow cytometer machines. Manufacturers are focused on creating instruments that are powerful, user-friendly, and incredibly fast. A cutting-edge FACS flow cytometer can analyze and sort thousands of cells per second with unmatched accuracy. Recent innovations like multiplexing, higher throughput systems, and smarter data analysis software are making these tools indispensable. Case in point: In April 2024, Becton, Dickinson and Company launched the BD FACSDiscover S8 Cell Sorter. This advanced spectral cell sorter, a prime FACS flow cytometer, combines real-time imaging with spectral analysis—a game-changer for detailed cellular purification. Restraints: The Cost Barrier Despite the benefits, high costs pose a challenge. Labs often require many flow cytometry instruments, leading to significant capital and maintenance expenses. For academic & research laboratories with restricted budgets, affording a high-end FACS flow cytometer can be tough. A single flow cytometer machine can cost over USD 500,000, and FACS flow cytometer-based cell sorters are typically pricier than cell analyzers due to their precision. This cost can slow adoption, especially in emerging countries. Opportunities: Expanding Clinical Horizons Increased use in clinical applications and infectious disease diagnostics is a massive opportunity. A cell cytometer, particularly a precise FACS flow cytometer, is invaluable for disease diagnosis, prognosis, and monitoring. In hematology, it's key for leukemia and lymphoma diagnosis, identifying rare cancer cells. In immunology, it helps diagnose immunodeficiencies and autoimmune disorders. Example: In March 2024, Beckman Coulter's DxFLEX Clinical Flow Cytometer received USFDA clearance, validated for 10-color immunophenotyping for leukemia and lymphoma—a clear win for clinical FACS flow cytometer applications. Challenges: Reagent Complexity Complexities related to reagent development present a notable challenge. These reagents (like fluorescently labeled antibodies and dyes) are vital for any flow cytometer machine, including FACS flow cytometer systems. Creating high-quality, specific, and stable reagents is time-consuming and resource-intensive, requiring extensive testing to ensure accurate, reproducible results across diverse applications. Request Sample Pages: Who's Driving Growth? Market Segments & Global Leaders Reagents & Consumables: This segment dominated the flow cytometry market in 2023 , essential for any flow cytometer machine , especially advanced FACS flow cytometer systems. This segment dominated the , essential for any , especially advanced systems. Academic & Research Institutes: Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput FACS flow cytometer capabilities. Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput capabilities. North America: Led the global flow cytometry market in 2023 due to robust healthcare infrastructure, significant investment in research and development, and high adoption of advanced flow cytometry technologies. The Asia Pacific region is expected to show significant growth. Key market players like Becton, Dickinson and Company (US), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US) are continuously innovating, often focusing on new FACS flow cytometer models to strengthen their market position. Recent Developments: From Agilent's NovoCyte Opteon Spectral Flow Cytometer (May 2024) to Sony's FP7000 spectral cell sorter (October 2023) and BD's groundbreaking FACSDiscover S8 Cell Sorter (March 2023), these innovations highlight the rapid evolution of FACS flow cytometer technology. FAQs Shaping Industry Conversations: 1. What is the core purpose of a Flow Cytometer machine? A flow cytometer machine rapidly analyzes and sorts microscopic cells in fluid, using lasers to gather data on cell size, granularity, and specific markers via scattered light and fluorescence. Essential for both fundamental research and precise disease diagnosis. 2. How does a FACS Flow Cytometer elevate cellular analysis? A FACS flow cytometer goes beyond analysis. As an advanced cell cytometer, it physically separates and collects specific cell populations based on their characteristics. This allows for high-purity isolation of rare cells, crucial for in-depth research and therapeutic development. 3. Why is the global flow cytometry market experiencing such explosive growth? The global flow cytometry market is booming, projected to reach US$10.3 billion by 2032, driven by tech advancements (e.g., spectral analysis in FACS flow cytometer), rising adoption in clinical diagnostics, increasing chronic disease prevalence, and surging biopharmaceutical R&D. AI and machine learning further accelerate this expansion. 4. What are the key hurdles in adopting flow cytometry instruments? The main challenge is the high cost of instruments, often exceeding USD 500,000, especially for advanced FACS flow cytometer models. Complexities in reagent development also add to the operational cost, limiting adoption for smaller academic & research laboratories with restricted budgets. 5. How critical is flow cytometry in understanding cell cycle flow and diagnosing blood cancers? Flow cytometry is vital for studying cell cycle flow by analyzing cellular DNA content. Clinically, a FACS flow cytometer is indispensable for diagnosing hematological malignancies like leukemia and lymphoma, by precisely identifying and characterizing abnormal immune cell populations based on unique surface markers. For more information, Inquire Now! Related Reports: Single Cell Analysis Market Cell Based Assays Market Esoteric Testing Market Research Antibodies Market Cell Analysis Market Get access to the latest updates on Top Companies in Flow Cytometry and Flow Cytometry Market Size Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
